Stockscreener 앱 받기
2.95
6.79%
-0.215
시간 외 거래:
3.02
0.07
+2.37%
전일 마감가:
$3.165
열려 있는:
$3.17
하루 거래량:
930.04K
Relative Volume:
0.57
시가총액:
$209.93M
수익:
-
순이익/손실:
$-192.96M
주가수익비율:
-0.8939
EPS:
-3.3
순현금흐름:
$-167.04M
1주 성능:
+4.98%
1개월 성능:
+30.53%
6개월 성능:
+41.83%
1년 성능:
+15.69%
1일 변동 폭
$2.905
$3.19
1주일 범위
$2.79
$3.3499
52주 변동 폭
$0.783
$3.39
Ventyx Biosciences Inc Stock (VTYX) Company Profile
명칭
Ventyx Biosciences Inc
전화
(858) 945-2393
주소
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
VTYX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.95 | 199.96M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-03-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-11-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Wells Fargo | Overweight |
| 2022-12-19 | 개시 | Goldman | Buy |
| 2022-11-17 | 개시 | Morgan Stanley | Overweight |
| 2022-09-07 | 개시 | Stifel | Buy |
| 2022-09-01 | 개시 | H.C. Wainwright | Buy |
| 2022-05-09 | 개시 | Credit Suisse | Outperform |
| 2022-03-31 | 개시 | Canaccord Genuity | Buy |
| 2022-02-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-15 | 개시 | Jefferies | Buy |
| 2021-11-15 | 개시 | Piper Sandler | Overweight |
모두보기
Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스
Ventyx Biosciences Inc. Stock Analysis and ForecastConsistently high yield - Autocar Professional
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth? - Yahoo Finance
What drives Ventyx Biosciences Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Is Ventyx Biosciences Inc. a good long term investmentRecord-breaking capital gains - Autocar Professional
What analysts say about Ventyx Biosciences Inc. stockBreakout stock performance - Autocar Professional
What makes Ventyx Biosciences Inc. stock price move sharplyFree Insider Trading Tips - Newser
Why Ventyx Biosciences Inc. stock attracts strong analyst attentionConsistent High Return Strategy - Newser
How Ventyx Biosciences Inc. stock performs during market volatilityAlpha Stock Ideas - Newser
Wealth Enhancement Advisory Services LLC Invests $28,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Analyzing the Impact of Earnings Reports on Ventyx Biosciences Inc Inc. (VTYX) Price Performance - investchronicle.com
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Shareholders - ACCESS Newswire
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000E Index - MarketScreener
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Rhumbline Advisers - Defense World
Canaccord maintains buy rating on Ventyx stock after positive trial results - Investing.com
Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance
Ventyx Therapeutics' VTX3232: A Neuroinflammation Breakthrough with Orphan Drug Pricing Power - AInvest
Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com
Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results - MSN
Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener
Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com
Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - yahoo.co
Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch
Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha
Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView
Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India
VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus
Piper Sandler maintains $21 target on Ventyx stock By Investing.com - Investing.com Nigeria
Traders Buy Large Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX) - Defense World
Ventyx Biosciences reports annual meeting results By Investing.com - Investing.com India
Ventyx Biosciences reports annual meeting results - Investing.com
Piper Sandler maintains $21 target on Ventyx stock - Investing.com
As Ventyx Approaches Multiple Phase II Readouts, What Could Be Next For The Stock? - RTTNews
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Squarepoint Ops LLC - Defense World
Ventyx Biosciences Inc (VTYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):